Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review

  • Jaqueline Pinheiro de Alencar Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Francisco Matheus Prado Luna Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Matheus Barbosa Coelho Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Raissa Maria Rolim Bem de Morais Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • José Antonio de Lima Neto Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Messias Silvano da Silva Filho Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil. Scholarship of Scientific Initiation, Brazil
  • Ivana Rios Rodrigues Department of Clinical Care Nursing and Health, Ceara State University - UECE, Fortaleza, Ceara, Brazil
  • Marcial Moreno Moreira Department of Health Sciences, Faculty of Medicine of ABC – FMABC, Santo André, São Paulo, Brazil
  • David de Sousa Gregório
  • Modesto Leite Rolim Neto Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil. Department of Medicine, Federal University of Cariri - Barbalha, Ceará, Brazil. Department of Health Sciences, Faculty of Medicine of ABC – FMABC, Santo André, São Paulo, Brazil.

Abstract

Background: The Irisin is a myokine associated with the improvement on insulin resistance caused by diet and increased physical energy expenditure. Recent studies have shown that patients with Type 2 Diabetes Mellitus (T2DM) have reduced levels of irisin, showing it as a potential marker for various endocrine and cardiovascular diseases. This study aimed to verify if T2DM patients never treated or without ongoing treatment have reduced levels of irisin when compared to individuals with other metabolic profiles.


Methods and Findings: Systematic review of the literature, considering the primary studies published in 2012 to 2016, with the outcome Irisin levels in patients never treated or without current treatment in the ambience of Type 2 Diabetes Mellitus. The search was conducted through the electronic database Scopus (Elsevier), using the key words: "Irisin", "Human" and "Diabetes Mellitus". From the 91 studies found, 8 met the eligibility criteria. Significant differences were found on levels of irisin in patients with T2DM compared to normoglycemic individuals, obese and/or pre-diabetic. On average, there was a reduction of 15 pg/ml in plasma levels of irisin in diabetics. However, a minority of studies says that this relationship does not exist.


Conclusion: Irisin reduced levels were found in patients with T2DM and is also related to lipid profile, with the risk of developing endocrine diseases, such as diabetes and obesity, and high risk for cardiovascular diseases because of its relationship with endothelial dysfunction. This generates the need for research in order to explore the isolation and clinical use of irisin for treatment of disorders related to imbalance in energy demand, obesity and diabetes.


Descriptors: Irisin, Human, Diabetes Mellitus.

Published
May 12, 2017
How to Cite
DE ALENCAR, Jaqueline Pinheiro et al. Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review. International Archives of Medicine, [S.l.], v. 10, may 2017. ISSN 1755-7682. Available at: <http://imedicalsociety.org/ojs/index.php/iam/article/view/2552>. Date accessed: 29 may 2017. doi: http://dx.doi.org/10.3823/2441.
Section
Endocrinology